Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Trauma ; 68(5): 1078-83, 2010 May.
Artículo en Inglés | MEDLINE | ID: mdl-20453762

RESUMEN

BACKGROUND: Recent studies suggest that intraluminal pancreatic enzymes play a major role in the initiation of the inflammatory cascade by the gut after hemorrhagic shock. Previous animal models have shown that the inhibition of enteral pancreatic enzymes with a serine protease inhibitor, nafamostat mesilate (NM), decreases leukocyte activation and transfusion requirements after hemorrhagic shock. The objective of this study was to determine whether enteroclysis with NM would improve the clinical outcomes in swine after hemorrhagic shock and intestinal hypoperfusion. METHODS: Thirty-three male Yucatan minipigs weighing 25 kg to 30 kg underwent a controlled hemorrhage of 25 mL/kg with mesenteric clamp for further gut ischemia. Animals were allocated to three groups: (1) shock only (n = 15), (2) shock + enteroclysis with 100 mL/kg GoLYTELY (GL) as a carrier (n = 11), and (3) shock + enteroclysis with GL + 0.37 mmol/L NM (GL+NM, n = 7). Animals were resuscitated, recovered from anesthesia, observed for 3 days, and graded on a daily 4-point clinical scoring system. A score of 0 indicated a moribund state or early death, and a score of 4 indicated normal behavior. RESULTS: Pigs treated with GL + NM had significantly higher mean postoperative recovery scores (3.8 +/- 0.4, essentially normal behavior with no early deaths) compared with animals within the shock only and shock + GL groups (2.1 +/- 1 with one early death and 2.2 +/- 1.2 with two early deaths, respectively, analysis of variance p < 0.003). CONCLUSION: The inhibition of intraluminal pancreatic enzymes using enteroclysis with the serine protease inhibitor, NM, after hemorrhagic shock significantly improves the clinical outcome.


Asunto(s)
Guanidinas/uso terapéutico , Páncreas , Inhibidores de Serina Proteinasa/uso terapéutico , Choque Hemorrágico/tratamiento farmacológico , Análisis de Varianza , Animales , Benzamidinas , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Duodenostomía , Electrólitos/uso terapéutico , Nutrición Enteral , Guanidinas/inmunología , Guanidinas/farmacología , Leucocitos/efectos de los fármacos , Masculino , Insuficiencia Multiorgánica/etiología , Insuficiencia Multiorgánica/prevención & control , Páncreas/efectos de los fármacos , Páncreas/enzimología , Polietilenglicoles/uso terapéutico , Resucitación/métodos , Inhibidores de Serina Proteinasa/inmunología , Inhibidores de Serina Proteinasa/farmacología , Choque Hemorrágico/complicaciones , Choque Hemorrágico/enzimología , Choque Hemorrágico/inmunología , Choque Hemorrágico/mortalidad , Porcinos , Porcinos Enanos , Síndrome de Respuesta Inflamatoria Sistémica/etiología , Síndrome de Respuesta Inflamatoria Sistémica/prevención & control , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA